Overview

Study Evaluating TMI-005 in Active Rheumatoid Arthritis

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer